Orthocell Chairman John Van Der Wielen recently spoke with podcast host Chris Judd on Talk Ya Book to discuss the Company’s journey and exciting plans for global expansion with its regenerative medicine technologies.
Orthocell has announced the submission of its U.S. FDA 510(k) regulatory application for clearance to commercially distribute Remplir™ into the US$1.6 billion 1 U.S. nerve repair market.
Orthocell CEO & MD, Paul Anderson, recently joined Micahel Frazis on the Frazis Capital Podcast.
Orthocell has today announced the achievement of first sales of Remplir™ in Singapore, marking another significant milestone in its global commercialisation strategy.
Orthocell has been featured in The Australian Financial Review in an article by Health Editor Michael Smith titled “Perth’s billionaires pile into medtech Orthocell”.
Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating Remplir as a safe and effective biological medical device for use in the surgical repair of peripheral nerves.
Orthocell has been featured in The Australian Business Review, following today’s announcement that the US FDA 510(k) regulatory study of peripheral nerve-repair product Remplir meets all endpoints.
Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair device Remplir™ in Singapore.
Orthocell Chairman John Van Der Wielen spoke with Stockhead to discuss the Company’s strategic positioning ahead of its US market entry, sharing insights on why Remplir represents a compelling investment opportunity.
The fourth episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring Independent Director, Dr. Ravi Thadhani.